Literature DB >> 15722167

Intracellular targeting of polymer-bound drugs for cancer chemotherapy.

Aparna Nori1, Jindrich Kopecek.   

Abstract

Macromolecules have been traditionally employed as drug carriers due to their ability to selectively accumulate in malignant tissues compared to healthy tissues by either passive or active targeting, thus precluding undesirable side effects generated by free drug. The therapeutic activity proffered by such conjugates requires that the drug concentrate at its specific subcellular target such as the nucleus. Thus, the suitability of macromolecules as carriers also extends to their propensity to deliver the drug to a predetermined intracellular location. As binding a macromolecule to a drug facilitates cellular uptake by endocytosis, various approaches have been employed to either guide the drug to targets different from endosomal/lysosomal compartments by mediating vesicular escape, or to directly accomplish intracellular (cytoplasmic and nuclear) localization. This review discusses the utility of macromolecules in drug delivery and describes the numerous modalities (with a focus on cell-penetrating peptides) currently available for achieving effective intracellular drug delivery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15722167     DOI: 10.1016/j.addr.2004.10.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  51 in total

Review 1.  Nanoparticle mediated non-covalent drug delivery.

Authors:  Tennyson Doane; Clemens Burda
Journal:  Adv Drug Deliv Rev       Date:  2012-06-01       Impact factor: 15.470

2.  Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].

Authors:  Hui Ding; Satoshi Inoue; Alexander V Ljubimov; Rameshwar Patil; Jose Portilla-Arias; Jinwei Hu; Bindu Konda; Kolja A Wawrowsky; Manabu Fujita; Natalya Karabalin; Takako Sasaki; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

4.  Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Authors:  Carlos M Galmarini; Galya Warren; Madapathage T Senanayake; Serguei V Vinogradov
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

Review 5.  Polymer architecture and drug delivery.

Authors:  Li Yan Qiu; You Han Bae
Journal:  Pharm Res       Date:  2006-01-11       Impact factor: 4.200

6.  Multilayered films fabricated from an oligoarginine-conjugated protein promote efficient surface-mediated protein transduction.

Authors:  Christopher M Jewell; Stephen M Fuchs; Ryan M Flessner; Ronald T Raines; David M Lynn
Journal:  Biomacromolecules       Date:  2007-02-02       Impact factor: 6.988

Review 7.  Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.

Authors:  Gene L Bidwell; Drazen Raucher
Journal:  Adv Drug Deliv Rev       Date:  2010-05-15       Impact factor: 15.470

Review 8.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

9.  Distinct mechanisms of membrane permeation induced by two polymalic acid copolymers.

Authors:  Hui Ding; Jose Portilla-Arias; Rameshwar Patil; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2012-10-09       Impact factor: 12.479

10.  Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.

Authors:  Bong-Seop Lee; Manabu Fujita; Natalya M Khazenzon; Kolja A Wawrowsky; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.